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Abstract
Human naı ¨ve CD4 T cells express low levels of the immunomodulatory receptor CD300a, whereas effector/memory CD4
cells can be either CD300a
+ or CD300a
2. This suggested that CD300a expression could define a specific subset within the
effector/memory CD4 T cell subpopulations. In fact, ex vivo analysis of the IFN-c producing CD4 T cells showed that they are
enriched in the CD300a
+ subset. Moreover, stimulated CD4 T cells producing TNF-a and IL-2 besides IFN-c (polyfunctional)
are predominantly CD300a
+. In addition to producing markedly higher levels of Th1-associated cytokines, the stimulated
CD300a
+ CD4 T cells are distinguished by a striking up-regulation of the T-box transcription factor eomesodermin (Eomes),
whereas T-bet is up-regulated in both CD300a
+ and CD300a
2 activated CD4 T cells to similar levels. The pleiotropic cytokine
TGF-b1 has a determinant role in dictating the development of this Th1 subset, as its presence inhibits the expression of
CD300a and down-regulates the expression of Eomes and IFN-c. We conclude that CD300a
+ human Th1 cells tend to be
polyfunctional and after stimulation up-regulate Eomes.
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Introduction
Upon encountering antigen in secondary lymphoid organs,
naı ¨ve CD4 T cells differentiate into at least four functionally
distinct subsets: Th1, Th2, Th17 and induced regulatory T (iTreg)
cells [1]. Th1 cells make IFN-c and confer immunity against
intracellular pathogens [1,2]. Th1 cells are also involved in the
pathogenesis and maintenance of certain autoimmune conditions
[1,3–4]. Th2 cells produce IL-4, IL-5 and IL-13 and mediate the
response against extracellular parasites and they are involved in
the induction of allergic diseases and asthma [5]. Th17 cells make
IL-17a, IL-17f, IL-21 and IL-22, mediate immune responses
against fungi and extracellular bacteria [1,6–7], and have a role in
the pathogenesis of some autoimmune diseases [8]. iTregs produce
TGF-b1, IL-10 and IL-35, and play a critical role in maintaining
self-tolerance and regulating immune responses [1,9–12].
The cytokines and transcription factors that regulate the fate
commitment of CD4 cells have been the subject of very intense
investigation. Th1 differentiation is promoted by IL-12 and IFN-c
[1,13]. These cytokines, together with TCR mediated signals, are
very important for the expression of the key fate-determining or
master transcription factor of Th1 cells T-bet, a member of the T-
box transcription factor family [1,13–14]. Beside T-bet, other
lineage specific genes are expressed by Th1 cells. For example, T-
bet induces IL-12Rb2 expression by differentiating Th1 cells [15].
Then, these differentiating Th1 cells can be selected and expanded
by IL-12 produced by APCs [16]. Runx3 is another transcription
factor that cooperates with T-bet for maximal production of IFN-c
and silencing the gene encoding IL-4 in Th1 cells [17]. Other
transcription factors important in Th1 development are STAT-1,
the major transducer of IFN-c signaling, which plays a critical role
in the IFN-c mediated induction of T-bet [18], and STAT-4, the
IL-12 signal transducer that is important for the amplification of
the Th1 response [19–20]. Along with these two STAT proteins,
eomesodermin (Eomes), another T-box transcription factor that is
critical for IFN-c production by CD8 T cells [21–23], has been
suggested to have a role in IFN-c production by murine CD4 T
cells [24–25].
The simultaneous measurement of cell surface receptors and
intracellular cytokines allows distinction among T cell subsets,
particularly in humans [26]. For instance, CCR5 and CXCR3
expression is associated with Th1 cells [27–28]. CD4 T cell subsets
also express different cytokine receptors that play crucial roles
both in their development and phenotypic maintenance. For
example, Th1 cells express high levels of IL-12Rb2 and IL-18Ra
[15,29–31]. The expression of surface receptors and intracellular
cytokines by each T cell subset likely reflects their distinct
functional roles. It should be noted that the general correlation
PLoS ONE | www.plosone.org 1 May 2010 | Volume 5 | Issue 5 | e10636of cell surface receptor expression and cytokine production with
particular T cell subsets is not exact [26].
The T cells can also be divided into subsets by the type and
number of cytokines that they produce. T cells that produce
multiple cytokines simultaneously are commonly referred to as
polyfunctional [32]. Several publications have shown that a higher
number of polyfunctional T cells is correlated with a better
prognosis during HIV infection and vaccine animals studies have
shown that the quality of the response, i.e. polyfunctionality, is
predictive of control of the infection following challenge [32–36].
Here, we report that the expression of the immunomodulatory
receptor CD300a defines two subsets of circulating human IFN-c
producing CD4 T cells. In vitro TCR stimulation of the CD300a
+
population led to marked stimulation of Th1 cytokine production
with polyfunctionality also correlating with CD300a expression.
Such stimulation also led to a striking up-regulation of Eomes
expression when compared with the CD300a
2 subset, whereas T-
bet up-regulation does not distinguish the CD300a
+ and CD300a
2
subsets. The pleiotropic cytokine TGF-b1 has a determinant role
in dictating the development of this Th1 subset, as its presence
inhibits the expression of CD300a and down-regulates the
expression of Eomes and IFN-c.
Results
Human circulating IFN-c producing CD4 T cells are
predominantly CD300a
+.
The immunomodulatory receptor CD300a is expressed on cells
of the myeloid and lymphoid lineages [37–43]. Although CD300a
is expressed on all NK cells [39], not all T and B lymphocytes
express this receptor ([40–41] and data not shown), suggesting that
CD300a expression by these cells may be a marker of specific T
cell subsets. To investigate this, we examined CD300a expression
by human CD4 T cell subsets. We found that naı ¨ve CD4 T cells,
which include the majority of the CD45RO
2 CD4 T cells from
human healthy donors, express low levels of this receptor, whereas
the CD45RO
+ population, which includes the effector and
memory cells, is divided into CD300a
+ and CD300a
2 populations.
Tregs, characterized by the phenotype CD25
+CD127
low [44], are
CD300a
2 (Figure 1).
Figure 1. Flow cytometric analysis of human peripheral blood CD4 T cells. In the upper panel, freshly isolated CD4 T cells were labeled with
anti-CD4, -CD45RO, and -CD300a mAb. The lymphocyte gate was determined according to the forward and side scatter parameters. Then CD45RO
expression was determined for the CD4
+ cells. The expression of CD300a was assessed in naı ¨ve cells (CD45RO
2, dashed line) and memory cells
(CD45RO
+, continuous line). In the lower panel, freshly isolated CD4 T cells were labeled with anti-CD4, -CD25, -CD127 and -CD300a mAb. After
electronically gating the CD4
+ cells, the expression of CD300a was assessed for the Treg cells (CD25
+CD127
low, continuous line) and non Treg cells
(dashed line). Results are representative of 12 healthy donors.
doi:10.1371/journal.pone.0010636.g001
CD300a+ Human CD4 T Cells
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further discriminate among Th effector memory subsets. To
investigate this, we stimulated purified human CD4 cells with PMA
and ionomycin and then categorized them according to their
signature cytokine production, i.e. Th1 (IFN-c), Th2 (IL-4) and Th17
(IL-17). We show that the IFN-c producing CD4 T cells are
predominantly CD300a
+ (,70%), whereas both the IL-4 and IL-17
producing CD4 T cells are equally distributed between the CD300a
+
and CD300a
2 subsets (Figure 2A). We then checked the level of
cytokine production by the stimulated cells by measuring the median
fluorescence intensity (MFI) of cytokine staining, a value known to be
correlated with the amount of cytokine produced by a T cell [32].We
observed that within the IFN-c producing cells the CD300a
+ subset
produced more IFN-c per cell than the CD300a
2 subset (Figure 2B).
These results indicate that not only are IFN-c producing cells
enriched in the CD300a
+ subpopulation, but also, on a per cell basis,
the CD300a
+ c e l l st e n dt op r o d u c eh i g h e rl e v e l so fI F N - c than the
CD300a
2 subset. We also checked the expression of the cytokine
receptor CXCR3, a chemokine receptor preferentially expressed on
Th1 cells [27–28], on the CD300a
+ and CD300a
2 subsets. Our
results show that for CD4
+CD45RO
+ cells the CD300a
+ subset is
predominantly CXCR3
+, confirming that Th1 cells are enriched in
the CD300a
+ subset (Figure 2C). Finally, and in order to further
confirm that Th1 cells are enriched in the CD300a
+ subset, we
measured the IFN-c production by Ag-specific CD4 cells. Healthy
donors were analyzed for their response to the antigens pp65 from
human cytomegalovirus (CMV pp65) and tetanus toxoid (TT). It is
estimated that more than 50–60% of the US population is CMV
+
and virtually everyone has been vaccinated for tetanus. We analyzed
four healthy donors and found that two responded to CMV pp65,
andallrespondedtoTT(datanotshown).ResultsshowninFigure2D
indicate that morethan 75% of the Ag-specific, IFN-cproducing cells
are positive for CD300a. We also measured the production of IL-2 in
response to the same antigens and found that more than 75% of the
IL-2 producing cells are CD300a
+ (Figure 2D). Altogether, the above
results indicate that the circulating pool of human Th1 cells is
predominantly CD300a
+.
As it has been previously shown that cytokine repertoire in Th
cells is regulated by cell division [45–47], we next considered the
possibility that the CD300a
+ subset may produce more IFN-c
because they proliferate at a higher rate than CD300a
2 cells. To
do this, we sorted CD4
+CD45RO
+ cells into CD300a
+ and
CD300a
2 subsets. We labeled these cells with CFSE and
stimulated them with anti-CD3 plus anti-CD28 mAb for 72 h.
Then, cells were rested for four days and briefly re-stimulated with
PMA plus ionomycin. As shown in Figure 3, although CD300a
2
cells tend to proliferate only slightly less than the CD300a
+ cells,
the fraction of IFN-c producing cells within each subset of dividing
cells is smaller for the CD300a
2 cells than in the CD300a
+ cells
supporting our previous observation (see above) that CD300a
2
cells intrinsically produce less IFN-c than CD300a
+ cells. We also
observed that more of the proliferating CD300a
+ cells are
CXCR3
+ than the CD300a
2 cells confirming the results obtained
ex vivo. However, the expression of the activation marker CD25 is
similar for both the CD300a
+ and CD300a
2 subsets, indicating
that there is no difference in the activation potential of each subset.
We also observed that the presence or absence of CD300a on the
cell surface is a permanent feature, namely, that it is maintained
throughout cell division under the culture conditions used in these
experiments.
CD300a
+ Th1 cells are polyfunctional.
Others have shown that there are differences in the quality of
effector cells based on whether they secrete multiple cytokines
[32–36]. The generation of Ag-specific polyfunctional CD4 and CD8
T cells during vaccination regimes has been directly correlated with
protection against subsequent parasite or viral challenge [35–36].
Moreover, the number of Ag-specific polyfunctional T cells is strongly
correlated with the outcome of certain infectious diseases [32]. Given
that CD300a
+ cells produce more IFN-c per cell (see Figure 2B) than
the CD300a
2 cells, we wanted to determine if the expression of
CD300acorrelateswithpolyfunctionality.First,weanalyzedforCD4
T cells producing combinations of IFN-c, TNF-a and IL-2. We
found that cells that produce two cytokines (IFN-c and IL-2 or IFN-c
and TNF-a)o rt h r e ec y t o k i n e s( I F N - c,I L - 2a n dT N F - a)s i m u l t a -
neously (polyfunctional) are markedly enriched in the CD300a
+
subset (Figure 4A). Of relevance to the correlation of IFN-c
production with CD300a expression, the MFI for IFN-c staining is
much greater for the CD300a
+ triple producers than for the
CD300a
2 triple producers (Figure 4B). However, the MFI for
TNF-a or IL-2 staining is the same in the CD300a
+ and CD300a
2
triple producers. Next, cells producing IFN-c plus TNF-a or IL-2 in
combination with IL-4 or IL-17 were enumerated. Although there
are very few triple positive cells for these combinations, results
presented in Figure 4C clearly show that polyfunctionality correlates
with CD300a expression. Altogether, our results indicate that Th1
cells, as classified by IFN-c production, contain a population of cells
enriched for CD300a expression that are markedly more polyfunc-
tional than the CD300a
2 cells.
Ex vivo activated CD300a
+ and CD300a
2 cells have a very
similar Th1 signature, but are distinguishable by cytokine
production and Eomes expression.
The above results indicate that human circulating Th1 cells are
enriched for CD300a expression. To further explore the molecular
signature associated with the CD300a
+ phenotype, we sorted
peripheral blood CD4
+CD45RO
+ cells into CD300a
+ and
CD300a
2 cells and extracted the RNA for analysis of cytokine
and transcription factor transcripts involved in Th1 development.
We observed (Figure 5A) that freshly isolated, unstimulated
CD300a
+ cells express approximately twice as much IFN-c,T -
bet and Eomes mRNA, and significantly more STAT-4 mRNA
than the CD300a
2 subset. There were no significant differences
between the two cell subsets in the IL-12Rb2, STAT-1 or Runx3
mRNA levels. Both IL-12Rb2 and Runx3 are known to be
involved in Th1 development downstream of T-bet [15,17]. Jak3
has also been implicated in Th1 development [48], and we
observed that the Jak3 mRNA levels are slightly decreased in the
CD300a
+ subset compared to the CD300a
2 subset. Overall, these
results support the view that Th1 cells are enriched in the
CD300a
+ subset. On the other hand, the IL-13, IL-17A and IL-22
mRNA levels are significantly decreased in the CD300a
+ subset
compared to the CD300a
2 subset, indicating that Th2 and Th17
cells are not enriched for CD300a expression.
The sorted CD300a
2 and CD300a
+ populations were stimu-
lated overnight with anti-CD3 or anti-CD3 plus anti-CD28 mAb.
Then, we measured cytokine mRNA (Figure 5B) and cytokine
levels in the culture supernatant (Figure 5C). The results clearly
show that production of the Th1 signature cytokine, IFN-c, and
other cytokines associated with Th1 cells, TNF-a and IL-2, are
dramatically higher for the TCR activated CD300a
+ cells. This
agrees with the results reported above for cells stimulated with
PMA and ionomycin. No other cytokines show a significant
difference in their levels of production.
Because TCR stimulation shows that CD300a expression
strongly correlates with a higher production of IFN-c,w e
suspected that the transcription factors important for Th1
development, namely T-bet, Eomes, Runx3, STAT-1 and
CD300a+ Human CD4 T Cells
PLoS ONE | www.plosone.org 3 May 2010 | Volume 5 | Issue 5 | e10636Figure 2. Human circulating IFN-c producing CD4 T cells are enriched in the CD300a
+ subset. (A) Flow cytometric analyses for the
production of IFN-c, IL-4 and IL-17 in combination with cell surface expression of CD300a by purified CD4 T cells stimulated with PMA and ionomycin
for 4–5 h. The lymphocyte gate was determined according to the forward and side scatter parameters. The CD300a expression was determined for
CD300a+ Human CD4 T Cells
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12Rb2, would be differentially expressed by activated CD300a
+
and CD300a
2 cells. We were surprised to find that TCR
stimulation increased the expression of T-bet mRNA, the master
transcription factor for Th1 development, to the same degree in
both CD300a
+ and CD300a
2 cells (Figure 6A). Consequently, the
induced expression levels of IL-12Rb2 mRNA were the same, as
IL-12Rb2 is a target gene of T-bet [15]. None of the other mRNAs
measured showed a significant difference in the levels of expression
between CD300a
+ and CD300a
2 cells except for the T-box
transcription factor, Eomes. We observed a dramatic increase in
Eomes mRNA expression in the CD300a
+ subset after TCR
stimulation relative to the CD300a
2 subset. Then, we determined
by flow cytometric analysis if the activated CD300a
+ subset has
higher levels of Eomes protein than the activated CD300a
2 subset.
To do that, purified CD4 T cells were stimulated with anti-CD3
plus anti-CD28 mAb and the IFN-c producing cells were
identified by intracellular staining. Results in Figure 6B show that
T-bet was equally expressed by both the CD300a
+ and CD300a
2
IFN-c producing cells, while Eomes was expressed at higher levels
by the CD300a
+ subset. Altogether, these results show that the
CD300a
+ and CD300a
2 cells have a very similar Th1 signature
except, after stimulation, the CD300a
+ cells up-regulate Eomes
expression and tend to produce significantly larger amounts of
IFN-c, often in association with TNF-a and/or IL-2.
Th1 polarization in the presence of TGF-b1 induces
down-regulation of IFN-c and Eomes, but not T-bet
expression.
Our results indicate that CD300a expression distinguishes a
major human memory CD4 Th1 cell population that upon TCR
stimulation produces relatively high levels of IFN-c,o f t e ni n
association with other cytokines (polyfunctional capability), and
markedly up-regulates the expression of Eomes. In order to
determine conditions that promote the development of these
CD300a
+ cells, we sorted naı ¨ve CD4 cells from human peripheral
blood and cultured them in different conditions. Cells cultured
under Th1 polarizing conditions are mostly CD300a
+ and this
population included most of the IFN-c producing cells
Figure 3. Proliferation and phenotype of CD45RO
+CD300a
+ and CD45RO
+CD300a
2 CD4 T cells. Proliferation, as measured by CFSE
dilution, of sorted CD45RO
+CD300a
+ and CD45RO
+CD300a
2 cells in response to plate bound anti-CD3 plus anti-CD28 mAb. After three days of
stimulation, cells were rested four additional days. After the resting period, the cell surface expression of CXCR3, CD25 and CD300a was measured.
IFN-c production was measured by intracellular staining after a brief stimulation with PMA and ionomycin for 4 h. The bar graph represents the
percentage of IFN-c
+ cells for each cell generation in the CD300a
+ and CD300a
2 subsets. Results shown are representative of four different donors.
doi:10.1371/journal.pone.0010636.g003
the cytokine producing cells. A representative healthy donor is shown. The bar graph represents the average 6 SEM of the percentage of CD300a
+
cells within each cytokine producing subset. Results are from 15–19 donors. (B) MFI of IFN-c expression in the cytokine producing memory CD300a
+
and CD300a
2 cells. (C) Expression of CXCR3 and CD300a by circulating memory CD4 T cells. Freshly isolated CD4 T cells were labeled with anti-CD4,
-CD45RO, -CD300a and -CXCR3. Dot plots are from CD4
+CD45RO
+ gated cells. Results from a representative donor are shown from four donors that
were analyzed. (D) PBMCs from healthy donors were stimulated overnight with CMV pp65 or TT in the presence of brefeldin A and then analyzed for
the production of IFN-c and IL-2 by memory CD4 T cells (CD4
+CD45RO
+). For the cytokine positive cells, the cell surface expression of CD300a was
measured. The response of two of the four donors analyzed is shown.
doi:10.1371/journal.pone.0010636.g002
CD300a+ Human CD4 T Cells
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polarizing conditions were mostly CD300a
2 and this population
included most of the IL-17 producing cells (Figure 7A). These in
vitro experiments are in agreement with the results obtained ex
vivo, where circulating memory Th1 cells are enriched for
CD300a expression and Th17 cells tend to be CD300a
2 (see
Figure 2A).
Using the in vitro differentiation assay, we sought to determine
what signals control the expression of CD300a, Eomes and IFN-c
production on effector/memory cells. TGF-b1 was an obvious
candidate to study because both Th17 cells and Treg cells require
this cytokine for their development, and our results show that Treg
cells are CD300a
2 and Th17 cells tend to be enriched in the
CD300a
2 subset. In fact, when naı ¨ve CD4 T cells are polarized
Figure 4. CD300a
+ CD4 T cells are more polyfunctional than CD300a
2 CD4 T cells. (A) Purified CD4 T cells were stimulated with PMA and
ionomycin for 4–5 h. Then, cells were stained for cell surface expression of CD300a and production of IFN-c and TNF-a and/or IL-2. The percentage of
double and triple producers in the CD300a
+ and CD300a
2 cells is shown. Each symbol represents a different donor. (B) Graphic representation of the
average 6 SEM of the MFI of IFN-c, IL-2 or TNF-a for the triple producers shown in panel A. (C) Purified CD4 T cells were stimulated with PMA and
ionomycin for 4–5 h. Then, cells were stained for cell surface expression of CD300a and the production of the indicated cytokines. The percentage of
triple cytokine producers in the CD300a
+ and CD300a
2 subsets is shown. Each symbol is a different donor.
doi:10.1371/journal.pone.0010636.g004
CD300a+ Human CD4 T Cells
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generating less IL-17 producing cells, the number of CD300a
2
cells decreased compared to cultures where TGF-b1 was present
(data not shown). Therefore, we analyzed the ability of TGF-b1t o
modulate the expression of CD300a by total CD4 cells. In
Figure 7B, we show that addition of TGF-b1 to cell cultures results
in a decreased number of cells expressing CD300a. This decrease
in the number of CD300a
+ cells correlated with the amount of
TGF-b1 present in the culture media. Next, we cultured cells
under Th1 polarizing conditions in the presence of TGF-b1. After
12 days in culture, cells were briefly re-stimulated with PMA and
ionomycin, and the expression of CD300a and the production of
IFN-c were determined. In Figure 7C, we show that the presence
of TGF-b1 during priming and differentiation of Th1 cells
induced a dramatic increase in the CD300a
2 cells. Under these
culture conditions, there was also a decrease in the frequency of
IFN-c producing cells and the majority of IFN-c producing cells
were in the CD300a
2 subset (Figure 7C). Finally, we looked at the
expression of T-bet and Eomes by the in vitro differentiated Th1
cells in a recall assay in the presence and absence of TGF-b1.
Results depicted in Figure 7D showed that the level of IFN-c
mRNA was much lower in cells that were cultured in the presence
of TGF-b1, which agrees with the intracellular staining results
presented in Figure 7C. We also observed that the levels of T-bet
mRNA expression in cells exposed or not to TGF-b1 were
relatively similar. On the other hand, the levels of Eomes mRNA
were extremely sensitive to the presence of TGF-b1 during the in
vitro differentiation of Th1 cells. Altogether, these results indicate
that TGF-b1 is a key factor in dictating the development of Th1
cells characterized by the absence of CD300a and Eomes
expression and by the production of less IFN-c per cell.
Discussion
We have identified a subset of human circulating Th1 cells that
are characterized by their expression of CD300a, the production
Figure 5. The cytokine and transcription factor signature of CD300a
+ and CD300a
2 human memory CD4 T cells. (A) Purified CD4 T cells
were sorted into CD45RO
+CD300a
+ (black bars) and CD45RO
+CD300a
2 (white bars). RNA was extracted and the levels of mRNAs were determined by
real-time PCR. Graphs represent the average 6 SEM. AU: arbitrary units. Data are from 5–6 donors. These data correspond to the untreated (none)
samples in Figures 5B and 6A. (B) Purified CD4 T cells were sorted into CD45RO
+CD300a
+ and CD45RO
+CD300a
2 and then stimulated overnight with
plate bound anti-CD3 or anti-CD3 plus anti-CD28 mAb. RNA was extracted from cells and specific cytokine mRNAs were quantified by real-time PCR.
(C) Supernatants from the cultures were harvested and the levels of cytokines were measured.
doi:10.1371/journal.pone.0010636.g005
CD300a+ Human CD4 T Cells
PLoS ONE | www.plosone.org 7 May 2010 | Volume 5 | Issue 5 | e10636Figure 6. CD300a
+ cells up-regulate Eomes after stimulation. (A) mRNAs for the indicated transcription factors, and IL-12Rb2 and Jak3 were
quantified by real-time PCR. Graph represents the average 6 SEM. AU: arbitrary units. Data are from 5–6 donors. (B) Purified CD4 T cells were
stimulated with plate bound anti-CD3 plus anti-CD28 mAb for 24 h. The lymphocyte gate was determined according to the forward and side scatter
parameters. Then cells were stained for cell surface expression of CD300a and for the intracellular expression of IFN-c. The expression of Eomes, T-bet
and CD300a was determined in the IFN-c
+ cells. Results are representative of three donors.
doi:10.1371/journal.pone.0010636.g006
CD300a+ Human CD4 T Cells
PLoS ONE | www.plosone.org 8 May 2010 | Volume 5 | Issue 5 | e10636of relatively large amounts of IFN-c on a per cell basis, tendency to
be polyfunctional in regard to cytokine production, and up-
regulation of the T-box transcription factor Eomes during the
recall response. The generation of this subset is negatively
regulated by the presence of TGF-b1 during priming and
differentiation. Our in vitro cultures with CD4 naı ¨ve T cells show
that Th1 polarization in the absence of TGF-b1 (Figure 7A and
7C) results in the generation of mostly CD300a
+ cells and the vast
majority of the IFN-c producing cells in these cultures are also
CD300a
+. These in vitro data correlate with the results obtained ex
vivo (Figure 2A) showing that the IFN-c
+ cells are predominantly
CD300a
+. However, more variability was found in the CD300a
expression by the IFN-c producing cells obtained ex vivo,
presumably reflecting the presence of TGF- b1 during the in vivo
priming and differentiation.
The simultaneous measurement of cell surface markers and
intracellular cytokines, particularly in human immunology, is
becoming a powerful tool for the identification of specific T cell
subsets [26]. For example, functionally distinct human CD4 T
cells can be identified according to the expression of chemokine
receptors [27–28]. However, the extent of this correlation between
CD4 T cell subsets and specific surface markers and/or cytokine
production is far from perfect [26]. T cell subsets can be further
distinguished by whether or not they produce multiple cytokines.
T cells capable of producing multiple cytokines have been termed
polyfunctional [32]. The fact that some CD4 cells are able to
produce more than one Th signature cytokine at once, for
example IFN-c and IL-17 together, suggests that the currently
defined Th populations may be dividable into subpopulations. In
line with this, we show that Th1 (IFN-c producing cells), Th2 (IL-4
producing cells) and Th17 (IL-17 producing cells) subsets can be
clearly divided into at least two subpopulations according to their
expression of the CD300a receptor. Nonetheless, like certain
chemokine receptors that are more associated with specific Th
subsets, we also show that Th1 cells are mostly, but not entirely
CD300a
+.
The major cytokines driving Th1 differentiation are IFN-c and
IL-12 [1,13], which respectively activate the transcription factors
STAT-1 and STAT-4. The expression of the master transcription
factor for Th1 differentiation, T-bet, is up-regulated by both IFN-
c and IL-12 in the presence of TCR mediated signals [13,18]. A
‘‘two loop model’’ has recently been proposed in which initial
TCR mediated signals plus IFN-c induce T-bet expression. Then,
after termination of the TCR signal, IL-12Rb2 expression is up-
regulated allowing IL-12 to induce a second wave of T-bet
expression [13]. This second wave of T-bet, along with the up-
regulation of other transcription factors such as Runx3, is required
for imprinting Th1 cells for IFN-c re-expression later on in the
Figure 7. TGF-b1 down-regulates the expression of CD300a and Eomes in Th1 cells. (A) Sorted naı ¨ve CD4 T cells were polarized under Th1
or Th17 conditions as described in materials and methods. At day 12, cells were stimulated with PMA and ionomycin for 4 h, after which the cell
surface expression of CD300a and the production of IFN-c or IL-17 was determined. Results from a representative donor are shown from four donors
that were analyzed. (B) Proliferation, as measured by CFSE dilution, of purified CD4 cells in response to plate bound anti-CD3 plus anti-CD28 mAb in
the absence or presence of increasing amounts of TGF-b1. After three days of stimulation cells were rested four additional days. After the resting
period, the cell surface expression of CD300a was measured. Results from a representative donor are shown from three donors that were analyzed.
(C) Sorted naı ¨ve CD4 T cells were polarized under Th1 conditions in the absence or presence of 5 ng/ml of TGF-b1. At day 12, cells were stimulated
with PMA and ionomycin for 4 h and the cell surface expression of CD300a and production of IFN-c were determined. Results from a representative
donor are shown from four donors that were analyzed. (D) Sorted naı ¨ve CD4 T cells were polarized under Th1 conditions in the absence or presence
of 5 ng/ml of TGF-b1. At day 12, cells were stimulated with plate bound anti-CD3 + anti-CD28 mAb overnight, followed by RNA extraction. Specific
mRNAs for IFN-c, T-bet and Eomes were quantified by real-time PCR. Bar graphs show the averages of the percentage decrease in the presence of
TGF-b1 6 SEM. Data are from 4 donors.
doi:10.1371/journal.pone.0010636.g007
CD300a+ Human CD4 T Cells
PLoS ONE | www.plosone.org 9 May 2010 | Volume 5 | Issue 5 | e10636recall response [13]. Our data show that the expression of T-bet is
up-regulated to similar levels in memory CD4 CD300a
+ and
CD300a
2 cells after TCR stimulation, indicating that other
transcription factors are involved in the differential production of
IFN-c by these two subsets during the recall response. Our results
suggest that Eomes is at least one of these factors if not the sole
responsible factor. Although the requirement for Eomes has been
primarily studied in the development of CTLs [21–23], recent
publications have shown that Eomes may also have an important
role in the development of mouse Th1 cells [24–25]. It has also
been shown that Eomes is epigenetically modified to a state that is
associated with gene activation in murine Th1 cells [49].
Our data suggest that there is a relationship between CD300a
and Eomes expression. Th1 cells are mostly CD300a
+ and up-
regulate Eomes, while Th17 cells are mostly CD300a
2 (our data)
and do not up-regulate Eomes [49]. This relationship is further
supported by the finding that murine Th17 cells have lower levels
of Eomes than naı ¨ve CD4 cells and that in Th17 cells Eomes is
epigenetically modified to a state that is associated with gene
repression [49]. In line with this, T-bet and Eomes double KO
mice have been shown to develop an anomalous CD8 T cell
response during viral infections that is characterized by the
production of large amounts of IL-17 and minimal amounts of
IFN-c by the virus specific CTLs [22].
TGF-b1 is known to potently inhibit Th1 development [50]. It
is not clear how TGF-b1 inhibits IFN-c expression [51–53]. Some
authors have proposed that TGF-b1 inhibits Th1 development
through down-regulation of T-bet [51]. Others have said that
TGF-b1 uses different mechanisms for controlling IFN-c expres-
sion during the priming and recall responses, with the differential
involvement of STAT-4 and T-bet [52]. Studies by Yang et al [25]
in mice have shown that T-bet independent IFN-c production and
Th1 development are very susceptible to suppression by IL-6 plus
TGF-b1. These two cytokines are very important cytokines for
mouse Th17 development. They showed that IL-6 plus TGF-b1
inhibited Eomes expression and that over-expression of Eomes is
able to inhibit the ability of these cytokines to down-regulate T-bet
independent IFN-c production [25]. Our results show that in
humans, the presence of TGF-b1, during priming and differen-
tiation, favors the development of Th1 cells that are characterized
by their ability to up-regulate T-bet during a recall assay to levels
that are similar to Th1 cells generated in the absence of TGF-b1,
whereas TCR induced expression of Eomes in the recall assay is
dramatically decreased if Th1 cells are generated in the presence
of TGF-b1. Thus, it appears that TGF-b1 is able to suppress the
development of the CD300a
+ Th1 subset that up-regulates Eomes
during the recall response.
Several publications have shown that a higher number of
polyfunctional T cells correlates with a better prognosis during
HIV infection [32–34,54]. Also, vaccine studies with animals have
shown that the higher the level of multifunctional T cells the better
the control of the infection following challenge [35–36]. From our
studies, we conclude that CD300a expression is a marker for
human memory CD4 T cell polyfunctionality. However, we
observed that CD300a
+ and CD300a
2 IFN-c producing cells are
equally polyfunctional if both IL-2 and TNF-a are co-produced,
but consistent with all of our findings, the production of IFN-c is
much lower on a per cell basis for the CD300a
2 cells.
Furthermore, the CD300a
2 population fails to up-regulate Eomes
after TCR stimulation and has fewer numbers of IFN-c
+IL-17
+
and IFN-c
+IL-4
+ double producing cells.
Regulation of immune responses by inhibitory receptors is
crucial for proper function of the immune system [55]. ITIM(s)
containing receptors control a vast array of cellular responses,
ranging from autoimmunity, graft versus host disease, allergy, to
cell death [55]. The role of CD300a inhibitory receptor during the
immune response and more specifically on T cell function remains
to be established. Our data show that the differential expression of
CD300a clearly distinguishes between two IFN-c producing Th1
subsets. An important point to consider is that, if CD300a
+ cells
encounter their antigen and the currently unknown CD300a
ligand at the same time, their TCR mediated signals would be
potentially down-modulated (data not shown). This suggests that
after TCR stimulation the polyfunctional Th1 cells, i.e. the
CD300a
+ Th1 cells, may need additional controls in order to
avoid Th1 mediated immunopathology.
In conclusion, we propose that there are at least two types of
human CD4 IFN-c producing cells that are distinguishable by the
expression of CD300a, and that TGF-b1 exposure favors the
development of the CD300a
2 subset. More studies are required to
delineate the exact roles that these two subsets play in T cell
mediated immunity.
Materials and Methods
Reagents
Antibodies and reagents used in this study were obtained from the
following vendors: purified and PE-Cy7 anti-CD3 (clone UCHT1),
PE-Cy7 and APC anti-CD4 (clone RPA-T4), PE-Cy7 anti-CD25
(clone BC96), purified anti-CD28 (clone CD28.2), FITC, PE-Cy7
and APC anti-CD45RO (clone UCHL1), APC anti-CD62L (clone
Dreg56), FITC anti-CD127 (clone eBioRDR5), FITC and APC anti-
IL-2 (clone MQ1-17H12), FITC anti-IL-4 (clone MP4-25D2), FITC
anti-IL-17a (clone eBio84DEC17), PE-Cy7 and APC anti-TNF-a
(clone Mab11) from eBioscience, Alexa 647 anti-Eomes (clone
WD1928).APCanti-CXCR3 (clone 1C6), PE-Cy7 and purified anti-
IFN-c (clone B27) from BD Biosciences. PE anti-CD300a (clone
E59.126) that recognizes a unique epitope in CD300a [56] is from
Beckman-Coulter. Purified blocking anti-IL-4 (clone 34019) from
R&D Systems. Goat anti-mouse (GAM) IgG From Jackson
ImmunoResearch Laboratories. All cytokines were from R&D
Systems except recombinant IL-2 that was from the NCI. PMA
and Ionomycin were purchased from Sigma. Tetanus Toxoid was
from Calbiochem and recombinant CMV pp65 from Miltenyi
Biotec. CFSE was purchased from Invitrogen. BD Cytofix/
Cytoperm Plus kits with GolgiPlug or GolgiStop were used for
intracellular cytokine detection and were purchased from BD
Biosciences. The Cytokine Bead Array (CBA) human Th1/Th2 kit
was purchased from BD Biosciences and the human IL-17A ELISA
from eBioscience.
Flow cytometry
Flow cytometry experiments were performed with a FACS
Calibur (BD Biosciences) and the data were analyzed using the
FlowJo software package (Treestar). Lymphocytes were electron-
ically gated based on the forward and side scatter parameters.
Depending on the experiment, cells were stained with two to four
different labeled mAb. Controls included both unstimulated cells
and isotype controls that are not included in the figures for clarity
purposes.
Cell isolation and sorting
Buffy coats were obtained from the NIH blood bank from
healthy donors. These studies were approved by the NIH and
FDA Ethical Committees. CD4 T cells were isolated by negative
selection with kits from Miltenyi Biotec (purity was .93%). Naive
CD4 T cells, based on a CD62L
+CD45RO
2 phenotype, and
memory CD45RO
+CD300a
+ and CD45RO
+CD300a
2 cells,
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facilities. After sorting, cells were resuspended in T cell medium:
IMDM medium (Invitrogen) containing 10% human AB serum
(Valley Biomedical) and supplemented with GlutaMAX (Invitro-
gen) and penicillin/streptomycin (BioSource International).
Cell proliferation, differentiation and activation assays
For activation experiments, purified (.93% of purity) CD4 T cells
were stimulated with PMA (50 ng/ml) plus Ionomycin (2 mM) for 4–
5 h in the presence of GolgiStop (monensin). Then, cell surface
receptor expression and intracellular cytokine staining were deter-
mined with the BD Cytofix/Cytoperm Plus kit following the
manufacturer instructions. A second set of activation experiments
was performed on freshly isolated and sorted CD45RO
+CD300a
+
and CD45RO
+CD300a
2 memory cells. After sorting, cells were
resuspended at 0.5–1610
6 cells/ml and seeded on anti-CD3 (1 mg/
well) or anti-CD3 (1 mg/well) plus anti-CD28 (5 mg/well) mAb
coated wells from a 24 well plate. Cells were cultured overnight and
the next day supernatants were collected for cytokine measurement
and cells were stored at 4uC in RNALater (Ambion) solution until
RNA was isolated. Cytokines in the supernatant were measured with
a Cytokine Bead Array (CBA) following manufacturer instructions.
IL-17A in the supernatant was measured by ELISA.
For proliferation assays, CFSE labeled CD45RO
+CD300a
+ and
CD45RO
+CD300a
2 memory CD4 T cells (0.5–1610
6 cells in
2 ml) were added to 24 well plates coated with anti-CD3 (1 mg/
well) plus anti-CD28 (5 mg/well) mAb in the presence of 50–
100 U/ml of IL-2. Cells were cultured for three days and then
transferred into non coated wells for four additional days. Then, a
fraction of the cells were collected and the expression of cell
surface markers was analyzed by flow cytometry. The rest of the
cells were stimulated with PMA (50 ng/ml) plus Ionomycin (2 mM)
for 4–5 h in the presence of GolgiStop (monensin) and then cells
were permeabilized and fixed and the production of IFN-c was
detected by intracellular staining.
For Ag specific IFN-c and IL-2 production, PBMC from
healthy donors were resuspended at 3610
6 cells/ml. Two ml of
cells were added to each well from a 24 well plate. Tetanus toxoid
(0.5 mg/ml) or CMV pp65 (3 ml/ml) was added to the wells. After
a 2–3 h period, 1 ml/ml of Golgi Plug (Brefeldin A) was added to
the cultures and the cells were incubated overnight. Next day,
IFN-c and IL-2 production were detected in the CD4
+CD45RO
+
memory cells by intracellular staining.
For differentiation assays, sorted naı ¨ve (CD62L
+CD45RO
2)
CD4 T cells were resuspended in T cell medium at 0.5–1610
6/ml.
Two ml of cells were added to each well of a 24 well plate coated
with anti-CD3 (1 mg/well) plus anti-CD28 (5 mg/well). For Th1
differentiation anti-IL-4 (10 mg/ml) mAb and IL-12 (20 ng/ml)
were added to the culture. In some Th1 differentiation assays,
TGF-b1 (1–5 ng/ml) was added at the beginning of the culture
and at day 7. For Th17 differentiation assays, IL-1b (10 ng/ml),
IL-6 (50 ng/ml), TGF-b1 (1–5 ng/ml), anti-IL-4 (10 mg/ml) mAb
and anti-IFN-c (10 mg/ml) mAb were added to the culture. IL-23
(20 ng/ml) was added to the culture at days 3 and 5 and, at day 7,
TGF-b1 was added again. IL-2 (20 U/ml) was added to all
cultures at day 5. At day 12, cells from Th1 and Th17 cultures
were harvested and briefly stimulated with PMA and Ionomycin
for 4–5 h in the presence of GolgiStop. Cell surface expression of
CD300a and intracellular cytokines were measured by flow
cytometric analyses. Other cells from the end of the Th1 and
Th17 cultures were added to anti-CD3 (1 mg/well) plus anti-CD28
(5 mg/well) mAb coated wells from a 24 well plate and cultured
overnight. Next day cells were harvested and RNA isolated for
measurement of IFN-c, T-bet and Eomes transcripts.
Real-time PCR
All cell samples for RNA isolation were stored at 4uCi nR N A L a t e r
(Ambion) solution. RNA isolation was carried out according to the
manufacturer’s protocol using RNAqueous4PCR kit (Ambion).
cDNA was made using Qscript
TM cDNA synthesis kit from Quanta
Biosciences. The real-time PCR was done according to the
manufacturer’s instructions on Roche LC480 real-time machine
using LightcyclerH 480 SYBR green I master supermix (Roche
Diagnostics). The primers for real-time PCR measurement for
human target genes IL-12Rb2, STAT1, STAT4, JAK1, RUNX3
and Eomes were bought from SA Biosciences Corporation and the
primers for IL-13, IL-22, IL-17A, T-bet, IFN-c, IL-10 and 18s rRNA
were obtained from Qiagen. All reactions were done in triplicates and
the average value of triplicates was used for calculating the relative
levels of each mRNA species. Relative quantification of the target
genes was made using the 2
nd derivative maximum method using the
Roche Lightcycler software and calculating the fold changes over the
18s rRNA levels. Melting curve analysis was performed at the end of
each real-time PCR run to make sure that amplification yields only
one specific product.
Statistical analysis
Quantitative data were analyzed using GraphPad Prism
software. The data were plotted as bar graphs or scatter plots,
and pair wise comparisons were examined by two-tailed paired
Student’s t-test with 99% of confidence interval. P,0.05 was
considered significant.
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